Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

23 Drugs in Development

23 Drugs in Development

DIGITAL CONTENT

28 NEWS #PharmaBuzz

media
28 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

23DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Brilaroxazine, 1239729-06-6, X8l60ba01i, 6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2h-benzo[b][1,4]oxazin-3(4h)-one, 2h-1,4-benzoxazin-3(4h)-one, 6-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-, 2h-1,4-benzoxazin-3(4h)-one, 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-

Molecular Formula

C₂₂H₂₅Cl₂N₃O₃

Molecular Weight

450.4 g/mol

InChI Key

PMKMNTBZJOXTJW-UHFFFAOYSA-N

FDA UNII

X8L60BA01I

Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism. As of May 2015, it is in phase III clinical trials for schizophrenia.

1 2D Structure

Brilaroxazine

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

6-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-4H-1,4-benzoxazin-3-one

2.1.2 InChI

InChI=1S/C22H25Cl2N3O3/c23-17-4-3-5-19(22(17)24)27-11-9-26(10-12-27)8-1-2-13-29-16-6-7-20-18(14-16)25-21(28)15-30-20/h3-7,14H,1-2,8-13,15H2,(H,25,28)

2.1.3 InChI Key

PMKMNTBZJOXTJW-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1CN(CCN1CCCCOC2=CC3=C(C=C2)OCC(=O)N3)C4=C(C(=CC=C4)Cl)Cl

2.2 Other Identifiers

2.2.1 UNII

X8L60BA01I

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Brilaroxazine

2. 1239729-06-6

3. X8l60ba01i

4. 6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2h-benzo[b][1,4]oxazin-3(4h)-one

5. 2h-1,4-benzoxazin-3(4h)-one, 6-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-

6. 2h-1,4-benzoxazin-3(4h)-one, 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-

7. 6-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2h-benzo(b)(1,4)oxazin-3(4h)-one

8. Brilaroxazin

9. Brilaroxazine [inn]

10. Unii-x8l60ba01i

11. Brilaroxazine [who-dd]

12. Schembl3404085

13. Bdbm312188

14. Dtxsid001136921

15. Db09226

16. Rp-5063

17. Us9604944, 15b (example 14)

18. Hy-109112

19. Cs-0077721

20. 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-2h-1,4-benzoxazin-3(4h)-one

21. 6-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-4h-1,4-benzoxazin-3-one

22. 2036070-48-9

2.4 Create Date

2010-09-07

3 Chemical and Physical Properties

Molecular Formula	C₂₂H₂₅Cl₂N₃O₃
Molecular Weight	450.4 g/mol
XLogP3	4.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	7
Exact Mass	449.1272971 g/mol
Monoisotopic Mass	449.1272971 g/mol
Topological Polar Surface Area	54 Å²
Heavy Atom Count	30
Formal Charge	0
Complexity	562
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Investigated for the treatment of schizophrenia and schizoaffective disorder.

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Brilaroxazine manufacturers, exporters & distributors on PharmaCompass

Brilaroxazine

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DEVELOPMENTS

23 Drugs in Development

DIGITAL CONTENT

28 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

23DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?